The Safety of Low-Molecular-Weight Heparin During and After Pregnancy.
In industrialized countries, venous thromboembolism remains a leading cause of mortality in pregnant women. Low-molecular-weight heparin (LMWH) is the most commonly recommended anticoagulant in pregnancy, having been proven effective and safe in multiple prospective clinical trials. The aim of this article is to outline existing recommendations for proper use of LMWH in pregnancy and data on risks of LMWH. Wereviewed guidelines froma number of professional societies.We also examined the current literature behind the various risks associated with LMWH use. Our review outlines the current data that guide the use of LMWH in pregnancy. With prophylactic dosing, LMWH comes with a 0.5% risk of antepartum bleeding and a 1% risk of postpartum hemorrhage that is not different from clinical trial controls. With treatment dosing, there is a 1.5% risk of antepartum bleeding and a 2% risk of postpartum hemorrhage. Overall, current evidence behind these risks is limited, and this review suggests areas of further study moving forward.